Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling
- 10 August 2022
- journal article
- research article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 61 (10) , 1427-1441
Abstract
Background The combination of polymyxins, meropenem, and sulbactam demonstrated efficacy against multi-drug-resistant bacillus Acinetobacter baumannii. These three antibiotics are commonly used against major blood, skin, lung, and heart muscle infections. Objective The objective of this study was to predict drug disposition and extrapolate the efficacy in these tissues using a physiologically based pharmacokinetic modeling approach that linked drug exposures to their target pharmacodynamic indices associated with antimicrobial activities against A. baumannii. Methods An adult physiologically based pharmacokinetic model was developed for meropenem, colistin, and sulbactam and scaled to pediatrics accounting for both renal and non-renal clearances. The model reliability was evaluated by comparing simulated plasma and tissue drug exposures to observed data. Target pharmacodynamic indices were used to evaluate whether pediatric and adult dosing regimens provided sufficient coverage. Results The modeled plasma drug exposures in adults and pediatric patients were consistent with reported literature data. The mean fold errors for meropenem, colistin, and sulbactam were in the range of 0.710–1.37, 0.981–1.47, and 0.647–1.39, respectively. Simulated exposures in the blood, skin, lung, and heart were consistent with reported penetration rates. In a virtual pediatric population aged from 2 to < 18 years, the interpretive breakpoints were achieved in 85–90% of subjects for their targeted pharmacodynamic indices after administration of pediatric dosing regimens consisting of 30 mg/kg of meropenem, and 40 mg/kg of sulbactam three times daily as a 3-h or continuous infusion and 5 mg/kg/day of colistin base activity. Conclusions The physiologically based pharmacokinetic modeling supports pediatric dosing regimens of meropenem/colistin/sulbactam in a co-administration setting against infections in the blood, lung, skin, and heart tissues due to A. baumannii.Keywords
Funding Information
- Shandong Provincial Natural Science Foundation (ZR2019BC025)
This publication has 79 references indexed in Scilit:
- Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and DevelopmentCPT: Pharmacometrics & Systems Pharmacology, 2013
- What Is the Efficacy and Safety of Colistin for the Treatment of Ventilator-Associated Pneumonia? A Systematic Review and Meta-RegressionClinical Infectious Diseases, 2012
- Clinical Pharmacokinetics of Meropenem and Biapenem in Bile and Dosing Considerations for Biliary Tract Infections Based on Site-Specific Pharmacodynamic Target AttainmentAntimicrobial Agents and Chemotherapy, 2011
- Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patientsAnnals of Intensive Care, 2011
- Penetration of Colistin into Cerebrospinal FluidAntimicrobial Agents and Chemotherapy, 2009
- Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative BacteriaAntimicrobial Agents and Chemotherapy, 2009
- Renal Disposition of Colistin in the Isolated Perfused Rat KidneyAntimicrobial Agents and Chemotherapy, 2009
- Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MSJournal of Pharmaceutical and Biomedical Analysis, 2009
- Multidrug-resistant Acinetobacter baumannii Pneumonia in Lung Transplant RecipientsThe Journal of Heart and Lung Transplantation, 2008
- Colistin Methanesulfonate Is an Inactive Prodrug of Colistin against Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2006